Roivant signals imminent brepocitinib data readout in dermatomyositis while advancing $500M share repurchase Roivant signals imminent brepocitinib data readout in dermatomyositis while advancing $500M share repurchase Post ContentroivRead More You might also be interested in reading Boeing’s shares rise on upbeat remarks from CFO. August 11, 2025 In Mainstream ← Previous post Next post →